Figure 2. Combination treatment with decitabine and cisplatin results in significant anti-tumor and antinociceptive effects.

(A) Combination treatment of decitabine and cisplatin produces a stronger anti-tumor effect in the preclinical model than either drug alone. Paw volume change from baseline (day 0 prior to cancer inoculation) are shown. Treatment with either decitabine or cisplatin alone produces a minor, non-sustained reduction in paw volume. Combination treatment with decitabine and cisplatin, however, produces sustained anti-tumor activity even after cessation of cisplatin treatment on PID 21. (B) The graph shows percent change in mechanical threshold from baseline. Mechanical threshold of mice treated with decitabine, cisplatin and combination treatment was significantly higher than the control groups on indicated days, signifying lower mechanical allodynia (*p<.05, **p<.01, ***p <.001, Two-way RM ANOVA, Holm-Sidak test, see Table 2).